BioSpace News Archive

Silk Road Medical, Inc. announced that effective as of market open on March 6, 2020, its common stock has been approved for uplisting to the Nasdaq Global Select Market® and will continue trading under its current ticker symbol “SILK”.

SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today reported 2019 full year financial results and announced product delivery expectations for oral TPOXX® under the HHSO100201800019C contract with the Biomedical Advanced Research and Development Authority (“BARDA”, and “19C BARDA Contract”, also known as the 2018 BARDA Contract)

Eloxx Pharmaceuticals, Inc. reported its financial results for the three and twelve months ended December 31, 2019 and provided a business update.

Ovid Therapeutics Inc. announced multiple poster presentations across its rare neurological disease platform at the American Academy of Neurology 2020 Annual Meeting in Toronto.

CNS Pharmaceuticals, Inc., a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, plans to report financial results for the three and 12 months ended December 31, 2019, after the close of the U.S. financial markets on Thursday, March 12, 2020..

Oncolytics Biotech® Inc., currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, announced its financial results and operational highlights for the quarter and year ended December 31, 2019.

Cryoport, Inc., a global leader in life sciences solutions, announced financial results for the three and twelve-month periods ended December 31, 2019.

PPD, Inc., a leading global contract research organization, announced that its management team will participate in the Barclays Global Healthcare Conference on March 11, 2020, at the Loews Miami Beach Hotel in Miami Beach, Florida.

Cash and cash equivalents totaled approximately $306 million at December 31, 2019

Signant Health is proud to announce the appointment of Ian Jennings as Chief Commercial Officer to help support the next phase of Signant Health’s growth as a leading advocate of patient focused technology solutions.